MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Thalidomide

Selected References

  • Brooks C, et al. 1977. Linear growth of children with limb deformities following exposure to thalidomide in utero. Acta Paediatr Scan 66:673-675.
  • Castilla E, et al. 1996. Thalidomide, a current teratogen in South America. Teratology 54:273-277.
  • Gao S, et al. 2020. Recent advances in the molecular mechanism of thalidomide teratogenicity. Biomed Pharmacother. ;127:110114. doi: 10.1016/j.biopha.2020.110114. Epub 2020 Apr 15.
  • Gollop T, et al. 1987. Prenatal diagnosis of thalidomide syndrome. Prenat Diagn 7:295-298.
  • Ito T, et al. 2020. Molecular mechanisms of thalidomide and its derivatives. Proc Jpn Acad Ser B Phys Biol Sci.;96(6):189-203.
  • Miller MT, et al. 2009. Thalidomide and misoprostol: Opthalmologic manifestations and associations both expected and unexpected. Birth Defects Res A Clin Mol Teratol. 85(8):667-676.
  • Peng X, et al. 2017. Thalidomide results in diminished ovarian reserve in reproductive age female IBD patients. Medicine (Baltimore) 96(21):e6540.
  • Prescriber Guide to (THALOMID REMS™) Risk Evaluation and Mitigation Strategy (REMS)™ Program. (2014). Retrieved from https://www.fda.gov/media/79047/download
  • Rodier PM, 2000. The Early Origins of Autism, Scientific American 282:56-63.
  • Rodier PM. 2002. Converging evidence for brain stem injury in autism. Dev Psychopathol. ;14(3):537-57.
  • Smithells R. 1992. Recognition of thalidomide defects. J Med Genet 29:716-723.
  • Sterling D, et al. 1997. Thalidomide: a surprising recovery. J Am Pharm Assn 3:306-313.
  • Stromland K, et al. 1993. Thalidomide embryopathy: revisited 27 years later. Acta Ophthalmol (Copen) 71:238-245.
  • Stromland K, et al. 1994 Autism in the thalidomide embryopathy: a population study. Dev. Med. Child Neurol. 36:351-356.
  • Vargesson N. 2019. The teratogenic effects of thalidomide on limbs. J Hand Surg Eur Vol.;44(1):88-95.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.